Company intelligence / Profile preview

ImagiRation

Boston/Cambridge area, Massachusetts, United Statesimagiration.com ↗

Ownership: Private
Development stage: Other

Overview

MITA demonstrated a 2.2-fold greater language improvement in children with autism compared to controls over a 3-year study of 6,454 children. The difference was statistically significant (p < 0.0001), as published in the journal Healthcare. Clinical trial NCT02708290 was completed.

Therapeutic areas: PsychiatryNeurology
Modalities: Non-pharmacological therapyDigital therapeutic (adaptive language therapy application)
Industry: Digital Health Medical Devices

Partnerships

MIT Global Literacy Project (“Curious Learning System” led by MIT/Tufts/Georgia State University)Boston University Center for Autism Research Excellence (“Apps for Language Enhancement Study”)

Beyond the preview

Go deeper on ImagiRation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImagiRation.

Explore the full profile